 Pyrazoles
"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 4 | 0 | 4 | | 2005 | 1 | 1 | 2 | | 2006 | 4 | 2 | 6 | | 2007 | 1 | 1 | 2 | | 2008 | 5 | 4 | 9 | | 2009 | 3 | 3 | 6 | | 2010 | 9 | 2 | 11 | | 2011 | 4 | 5 | 9 | | 2012 | 14 | 7 | 21 | | 2013 | 13 | 9 | 22 | | 2014 | 5 | 5 | 10 | | 2015 | 12 | 4 | 16 | | 2016 | 5 | 11 | 16 | | 2017 | 7 | 8 | 15 | | 2018 | 8 | 5 | 13 | | 2019 | 7 | 4 | 11 | | 2020 | 5 | 6 | 11 | | 2021 | 13 | 10 | 23 | | 2022 | 1 | 19 | 20 | | 2023 | 1 | 18 | 19 | | 2024 | 10 | 8 | 18 | | 2025 | 12 | 13 | 25 | | 2026 | 8 | 11 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Owen MC, Li DY, Shin H, Gu W, Parvathaneni A, Kadyrov FF, Wang X, Sticco-Ivins M, Bonnici G, Nelson SL, Dun H, Hyacinth S, Giangrasso SC, Chou C, Lin CY, Cain MT, Pedroza A, Dalal A, Sallam K, Boyd J, Woo J, Amrute JM, Cheng P, Lavine KJ, Kopecky BJ. Single-cell and spatial transcriptomics identify immune-stromal interactions in cardiac allograft vasculopathy. Nat Cardiovasc Res. 2026 May; 5(5):439-455.
-
Drilon A, Cho BC, Camidge DR, Nagasaka M, Besse B, Solomon B, Goto K, Wolf J, Popat S, Felip E, Yang N, de Langen AJ, Lu S, Velcheti V, Lin AL, Calvet CY, Li L, Tschaika M, Afsar S, Yang H, Lin JJ. Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. Oncologist. 2026 May 08; 31(6).
-
Soman P, Cuddy SAM, Gillmore JD, Sarswat N, Judge DP, Cappelli F, Stern LK, Wright R, Akinboboye O, Obici L, Bhatt K, Xiong K, Castaño A, Chen C, Falvey H, Pecoraro ML, Tamby JF, Sinha U, Fox JC, Shah K, Grodin JL, Ambardekar AV, Alexander KM, Khouri MG, Cheng RK. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 May 01; 11(5):446-454.
-
Ambardekar AV, Sarswat N, Wright R, Berk J, Davis MK, Garcia-Pavia P, Gillmore JD, Grodin JL, Mitchell JD, Mooney D, Nativi-Nicolau J, Poulsen SH, Ruberg FL, Chen C, Ji A, Siddhanti S, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Maurer MS, Cheng RK. Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
-
Downey DG, Houston C, Mayer-Hamblett N, Taylor-Cousar JL, Taggart CC. Contributors to the heterogeneity of response to CFTR modulators. Lancet Respir Med. 2026 Aug; 14(8):717-729.
-
Wyles DL, Matsuda K, Iwaki Y, Klonowski E. Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study. BMC Pulm Med. 2026 Apr 02; 26(1).
-
Van Braeckel E, Braun AT, Simmonds NJ, Barry PJ, Davies JC, Egan ME, Lapey A, Mall MA, McKone EF, Peckham D, Proesmans M, Ramsey B, Santamaria SV, Smith D, Taylor-Cousar JL, Tullis E, De Wachter E, Withers N, Ahluwalia N, Conner S, Jennings M, Lou Y, Weinstock TG, Keating D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis. J Cyst Fibros. 2026 Jul; 25(4):682-688.
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Avila JT, Skhisov D, Haines S, Navarro AC, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. Cancer Lett. 2026 Jun 28; 648:218467.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|